Department of Haematology, Oncology & Stem Cell Transplantation, University Medical Centre Freiburg & Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Department of Anesthesiology & Intensive Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
Future Oncol. 2020 Sep;16(25):1931-1939. doi: 10.2217/fon-2020-0486. Epub 2020 Jul 3.
Biosimilars have the potential to lower costs and increase patient access to life-saving cancer therapies. However, lack of familiarity with biosimilars can be a barrier to their adoption, limiting their health and economic benefits. As highly trusted healthcare providers, nurses play integral roles in patient education. This review aims to help prepare nurses to respond to potential questions from patients on biosimilars. The regulation, use and potential benefits of biosimilars are discussed, with a focus on biosimilars in oncology. Overall, biosimilars are highly regulated medicines that provide comparable benefits to available biologics. Nurses can influence the adoption of biosimilars through patient education and can impact the future of the field in their expanding roles within health care systems.
生物类似药具有降低成本和增加患者获得救命癌症疗法的潜力。然而，对生物类似药的不熟悉可能成为采用的障碍，限制了它们的健康和经济效益。作为高度可信的医疗保健提供者，护士在患者教育中发挥着不可或缺的作用。本综述旨在帮助护士准备好应对患者对生物类似药提出的潜在问题。本文讨论了生物类似药的监管、使用和潜在益处，重点关注肿瘤学中的生物类似药。总的来说，生物类似药是受到高度监管的药物，它们提供与现有生物制剂相当的益处。护士可以通过患者教育来影响生物类似药的采用，并通过在医疗保健系统中的扩展角色来影响该领域的未来。
